Theseus Pharmaceuticals (NASDAQ:THRX – Get Free Report) had its target price cut by analysts at Wedbush from $24.00 to $7.00 in a research report issued to clients and investors on Friday, MarketBeat reports. The firm currently has an “outperform” rating on the stock. Wedbush’s price objective would indicate a potential upside of 163.16% from the company’s current price.
A number of other analysts have also recently weighed in on the stock. HC Wainwright decreased their price target on shares of Theseus Pharmaceuticals from $22.00 to $9.00 and set a “buy” rating for the company in a research report on Friday. Needham & Company LLC downgraded Theseus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Theseus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.
Theseus Pharmaceuticals Price Performance
Theseus Pharmaceuticals stock opened at $2.66 on Friday. The company has a market cap of $115.91 million, a price-to-earnings ratio of -1.94 and a beta of 4.03. Theseus Pharmaceuticals has a 12 month low of $2.62 and a 12 month high of $14.77. The stock’s 50-day moving average is $9.46 and its 200-day moving average is $9.64.
Theseus Pharmaceuticals (NASDAQ:THRX – Get Free Report) last posted its quarterly earnings results on Thursday, May 11th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.08. Research analysts anticipate that Theseus Pharmaceuticals will post -1.58 EPS for the current year.
Hedge Funds Weigh In On Theseus Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in THRX. Tower Research Capital LLC TRC increased its stake in shares of Theseus Pharmaceuticals by 66.0% in the third quarter. Tower Research Capital LLC TRC now owns 4,420 shares of the company’s stock worth $26,000 after buying an additional 1,757 shares during the last quarter. Barclays PLC increased its position in shares of Theseus Pharmaceuticals by 76.0% in the 4th quarter. Barclays PLC now owns 8,904 shares of the company’s stock worth $44,000 after purchasing an additional 3,844 shares during the last quarter. American International Group Inc. raised its stake in shares of Theseus Pharmaceuticals by 39.2% in the 2nd quarter. American International Group Inc. now owns 7,952 shares of the company’s stock valued at $44,000 after purchasing an additional 2,238 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Theseus Pharmaceuticals by 68.3% during the second quarter. JPMorgan Chase & Co. now owns 9,084 shares of the company’s stock worth $50,000 after purchasing an additional 3,687 shares during the last quarter. Finally, Morgan Stanley grew its stake in Theseus Pharmaceuticals by 31.1% in the fourth quarter. Morgan Stanley now owns 11,478 shares of the company’s stock worth $57,000 after purchasing an additional 2,721 shares in the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.
Theseus Pharmaceuticals Company Profile
Theseus Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.
Featured Stories
Receive News & Ratings for Theseus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Theseus Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.